maturation inhibitors

maturation inhibitors

An experimental class of anti-HIV drugs that block protease action in a manner different from that of PROTEASE INHIBITORS. Maturaltion inhibitors act by blocking a site on the GAG protein where protease normally binds, that preventing the enzyme from clipping GAG correctly. In this way the capsid does not form and the virus is unable to infect other cells. A member of the class is a betulinic acid derivative called PA-457.
Mentioned in ?
References in periodicals archive ?
A new class of antiretroviral drugs, the maturation inhibitors, is now emerging, which target the internal structural precursor protein, Gag, and its function in final assembly of the mature infectious virion.
There are also other drugs in the integrase and CCR5 inhibitor classes that are in development, and additional promising new classes, such as maturation inhibitors, are being actively evaluated in clinical trials.
PA-1050040 represents one of a large number of second-generation maturation inhibitors currently in pre-clinical testing.
And just in case this particular compound turns out not to be safe and effective, the company has other potential maturation inhibitors ready, to take its place.
PA-457 is the first in a new class of HIV drugs called Maturation Inhibitors, which have a mechanism of action that differs from those of approved HIV drugs.
Key classes of mechanism of action include DNA polymerase inhibitors, Helicase-primase inhibitors, NFkB regulators, HSV-2 gene and nectin-1 receptor targetters, viral maturation inhibitors and PDI inhibitors.
McCallister will be responsible for medical affairs and will spearhead the company's Phase 3 development efforts for bevirimat, the company's lead candidate in a new class of oral HIV therapeutics called maturation inhibitors, discovered by Panacos scientists and their academic collaborators.
The second-generation maturation inhibitors, while structurally related to bevirimat, have the ability to overcome the amino acid polymorphisms found in some strains of HIV, which reduce the sensitivity of those viruses to bevirimat.
Maturation inhibitors were discovered by Panacos' scientists and their academic collaborators.
These actions are in line with our goal to secure partnerships or sale for our spectrum of HIV programs, including bevirimat, our second- and third-generation maturation inhibitors, as well as the oral fusion inhibitor program.
The assay provided activity data consistent with previous in vitro studies of bevirimat-resistant virus, suggesting that it is suitable for further development as a high-throughput phenotyping assay to measure the sensitivity of HIV from patients to bevirimat or other maturation inhibitors.